Mylan Loses Bid To Block Teva's Provigil Market Rights

Law360, New York (April 24, 2012, 2:13 PM EDT) -- A judge on Monday rejected Mylan Pharmaceuticals Inc.'s argument that Teva Pharmaceuticals USA Inc. and its affiliate Cephalon Inc. had worked together to stymie generic competition of sleep disorder drug Provigil and shot down Mylan's bid to block additional market exclusivity granted to Teva by federal regulators.

Mylan, which sued the U.S. Food and Drug Administration earlier this month in Washington federal court, lodged a preliminary injunction motion seeking to block the FDA's decision giving Teva 180-day exclusivity to market a generic version of Provigil. However,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.